Kelly Bilodeau

2 weeks ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. A birth control pill for men is progressing through the clinic after clearing a safety hurdle in its first human trial. The drug, which its developer YourChoice Therapeutics claims is the only non-hormonal male birth control pill in human studies, is in the midst of a second trial, putting it in contention to become the first oral contraceptive for men.

3 weeks ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy community. The patient died from acute liver failure , the only FDA-approved gene therapy for DMD. Its maker, Sarepta Therapeutics, the possibility that the treatment, which uses an adeno-associated virus vector to deliver its therapeutic gene payload, may have contributed to the fatality.

1 month ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. If the recent crop of companies emerging from stealth is any indication, innovators are doubling down on opportunities to join the juggernaut weight loss market while exploring fresh opportunities in immuno-oncology and pain management. Investors appear eager to back their efforts, pouring hundreds of millions into these new initiatives. The flow of capital reflects overall market trends.

1 month ago | supplychaindive.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. The Trump administration has intensified tariff pressure this month, moving to impose 25% levies on Canada and Mexico and reversing course to some degree while raising existing Chinese tariffs by 20% across the board. The administration has also promised the start of reciprocal tariffs next month.

1 month ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. Recurrent and metastatic cancers remain formidable challenges. But a recent radiopharmaceutical revival after years of stagnation could bring new options to the table. And If the drugs deliver on promises to expand into new types of cancer, they’ll unlock a vast market. Radiopharmaceuticals have been in use since the 1951 approval of radioactive iodine for thyroid conditions.